Watch MXCT. Know when insiders buy.
One email the day a filing lands. Free.
MXCT
MAXCYTE, INC.
1.19
−0.00 −0.42%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
35
FLAG · shorts 35
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $122.8MP/E —DIV YIELD —FCF YIELD -19.25%REV TTM $31.1M −13.2%NET INCOME −$35.6MNET CASH —52W 0.68 – 1.83SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $7.3M | −14.5% | 77.0% | −$10.2M | −$8.9M | — | -0.08 | −$4.7M | $62K | −$4.7M | Aug 13 |
| Q1 2026 · Mar 31 | $9.7M | −7.1% | 83.7% | −$6.2M | −$4.8M | — | -0.04 | −$8.2M | $72K | −$8.2M | Aug 13 |
| Q4 2025 · Dec 31derived | $7.3M | −16.0% | 77.9% | −$11.2M | −$9.6M | — | -0.09 | −$2.7M | $231K | −$2.9M | Mar 25 |
| Q3 2025 · Sep 30 | $6.8M | −16.4% | 76.6% | −$14.1M | −$12.4M | — | -0.12 | −$7.5M | $300K | −$7.8M | Nov 13 |
| Q2 2025 · Jun 30 | $8.5M | −18.4% | 82.1% | −$14.2M | −$12.4M | — | -0.12 | −$9.9M | $584K | −$10.4M | Aug 13 |
| Q1 2025 · Mar 31 | $10.4M | −8.4% | 85.6% | −$12.3M | −$10.3M | — | -0.10 | −$14.4M | $653K | −$15.1M | Aug 13 |
| Q4 2024 · Dec 31derived | $8.7M | −44.5% | 73.8% | −$12.9M | −$10.6M | — | -0.10 | −$7.8M | $147K | −$8M | Mar 25 |
| Q3 2024 · Sep 30 | $8.2M | +2.0% | 76.4% | −$14.1M | −$11.6M | — | -0.11 | −$4.4M | $406K | −$4.8M | Nov 13 |
| Q2 2024 · Jun 30 | $10.4M | — | 85.7% | −$12M | −$9.4M | — | -0.09 | −$4.8M | $294K | −$5.1M | Nov 13 |
| Q1 2024 · Mar 31 | $11.3M | — | 87.6% | −$12.3M | −$9.5M | — | -0.09 | −$10.6M | $804K | −$11.4M | Nov 13 |
| Q4 2023 · Dec 31derived | $15.7M | — | 90.0% | −$8.1M | −$5.3M | — | -0.05 | $981K | $915K | $66K | Mar 11 |
| Q3 2023 · Sep 30 | $8M | — | 90.1% | −$14M | −$11.3M | — | -0.11 | −$8.2M | $720K | −$9M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $33M | 81.2% | −$51.9M | −$44.6M | -135.1% | -0.42 | −$34.4M | $1.8M | −$36.2M | — | — |
| FY2024 · to Dec 31 | $38.6M | 81.6% | −$51.2M | −$41.1M | -106.3% | -0.39 | −$27.6M | $1.7M | −$29.3M | — | — |
| FY2023 · to Dec 31 | $41.3M | 88.5% | −$48.3M | −$37.9M | -91.8% | -0.37 | −$21.7M | $3.7M | −$25.4M | — | — |
| FY2022 · to Dec 31 | $44.3M | 88.5% | −$27.4M | −$23.6M | -53.3% | -0.23 | −$14.8M | $18.5M | −$33.3M | — | — |
| FY2021 · to Dec 31 | $33.9M | 89.2% | −$18.2M | −$19.1M | -56.3% | -0.21 | −$10.7M | $3.8M | −$14.5M | — | — |
| FY2020 · to Dec 31 | $26.2M | 89.4% | −$11.1M | −$11.8M | -45.2% | -0.17 | −$8.8M | $2.1M | −$10.9M | — | — |
Every number comes from MAXCYTE, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.